BCR-ABL kinase inhibitor and application thereof

A solvate, -NH2 technology, applied in the field of chemical medicine, can solve problems such as disease recurrence

Active Publication Date: 2015-04-29
NANJING SANHOME PHARM RES & DEV CO LTD
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The development and clinical use of imatinib has opened a new era of tumor molecular targeting, but long-term use of imatinib will cause drug resistance and lead to disease recurrence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • BCR-ABL kinase inhibitor and application thereof
  • BCR-ABL kinase inhibitor and application thereof
  • BCR-ABL kinase inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0139]Example 1 Preparation of 3-ethynyl-4-methyl-N-[4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl]benzamide

[0140]

[0141] Step 1 Preparation of 3-iodo-4-methyl-N-[4-(4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl]benzamide

[0142] 4-(4-Methylpiperazin-1-ylmethyl)-3-trifluoromethylaniline (2.27 g, 8.3 mmol), 3-iodo-4-methyl-benzoyl chloride ( 10mmol), 15ml tetrahydrofuran, 10ml triethylamine, stirred at room temperature for 4 hours. Add saturated NaHCO 3 Solution washing, ethyl acetate and water extraction, saturated NaCl solution washing, anhydrous NaCl 2 SO 4 After drying, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column to give the title compound as a yellow oil.

[0143] 1 H NMR (500MHz, CDCl 3 )δ:8.39(s,1H,N-H),8.29(s,1H,Ar-H),7.88(d,1H,Ar-H),7.86(s,1H,Ar-H),7.75(d,1H ,Ar-H),7.73(d,1H,Ar-H),7.28(d,1H,Ar-H),3.62(s,2H,PhCH 2 ),2.60(b,8H,4×-CH 2 ),2.47(s,3H,-CH 3 ),2.31(s,3H,-CH 3 ). ...

Embodiment 2

[0150] Example 2 3-((1H-pyrrolo[2,3-b]pyrazin-5-yl)ethynyl)-4-methyl-N-[4-((4-methylpiperazine-1- Base) methyl) -3-trifluoromethylphenyl] benzamide preparation

[0151]

[0152] Add the compound prepared in Example 1 (126mg, 0.3mmol), 5-bromo-1H-pyrrolo[2,3-b]pyrazine (59mg, 0.3mmol), Pd(PPh 3 ) 2 Cl 2 (63mg, 0.006mmol), CuI (18mg, 0.09mmol), 1mL Et 3 N and 5mL DMF, under the protection of inert gas, stirred at 80°C for 8 hours. After the reaction was completed, extract with ethyl acetate and water, combine the organic layers, wash with saturated NaCl solution, anhydrous NaCl 2 SO 4 dry. Concentration under reduced pressure and the residue was purified by silica gel column to obtain the compound as an off-white solid.

[0153] 1 H NMR (500MHz, CDCl 3 )δ:8.91(br,1H,-NH),8.46(s,1H,Ar-H),8.02(d,1H,Ar-H),7.98(s,1H,Ar-H),7.87(s, 1H,Ar-H),7.85(s,-NH,1H),7.78-7.80(m,1H,Ar-H),7.69-7.70(d,1H,Ar-H),7.60-7.62(m,1H ,Ar-H),7.35(d,1H,Ar-H),6.72-6.73(m,1H,Ar-H),3.61(s,2H,-CH 2...

Embodiment 3

[0155] Example 3 3-((1H-pyrrolo[2,3-b]pyrazin-5-yl)ethynyl)-4-methyl-N-[4-((4-methylpiperazine-1- Base) methyl) -3-trifluoromethylphenyl] benzamide hydrochloride

[0156] Weigh 3-((1H-pyrrolo[2,3-b]pyrazin-5-yl)ethynyl)-4-methyl-N-[4-((4-methylpiperazin-1-yl )methyl)-3-trifluoromethylphenyl]benzamide (30mg) was dissolved in 5mL of methanol, and ethyl hydrogen chloride solution was added dropwise to a pH value of about 3, stirred at room temperature for 3h, and evaporated under reduced pressure to remove the volatile The material was dried in vacuo at 50 °C for 5 h to afford the title compound.

[0157] 1 H NMR (300MHz, DMSO-d 6 )δ:12.34(s,1H),10.61(s,1H),10.25(b,1H),8.56(s,1H),8.26(s,2H),8.14(d,1H),7.96-8.01(m ,2H),7.73(d,1H),7.56(d,1H),6.67-6.69(m,1H),3.70(s,2H),3.37(m,4H),2.89-3.06(m,4H), 2.77(s,3H), 2.61(s,3H).

[0158] 1 H NMR (300MHz, DMSO-d 6 +D 2 O)δ:10.62(s,1H),8.57(s,1H),8.22(s,2H),8.07(d,1H),7.93-7.99(m,2H),7.74(d,1H),7.56( d,1H),6.71(d,1H),3.70(s,2H),3.38-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the field of chemical medicines, in particular to compounds as represented by formula I having BCR-ABL kinase inhibitory activity, or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof, and pharmaceutical composition containing the compounds, and application of the compounds or compositions in drug preparation. The compounds of the present invention have strong inhibitory effect on BCR-ABL kinase, and can be used to treat diseases such as tumors.

Description

technical field [0001] The invention belongs to the field of chemical medicine, and in particular relates to a class of compounds with BCR-ABL kinase inhibitory activity or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, as well as pharmaceutical compositions containing these compounds and Application of these compounds or compositions in the preparation of medicines. Background technique [0002] Protein tyrosine kinases (PTKs) are a class of kinases that can catalyze the transfer of γ-phosphate on ATP to protein tyrosine residues. A protein enzyme system that acts on a functional protein. Protein tyrosine kinases (PTKs) play a very important role in intracellular signal transduction pathways, regulating a series of physiological and biochemical processes such as cell growth, differentiation, and death. The abnormal expression of protein tyrosine kinase can lead to the disorder of cell proliferation regulation, and then lead to the occu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D487/04C07D519/00A61K31/4985A61K31/4995A61P35/00A61P35/02
CPCC07D487/04C07D519/00A61K31/4985A61K31/4995A61P35/00A61P35/02A61P35/04
Inventor 王勇赵立文刘阳张景忠王德忠高毅平陈宏雁张仓张迪
Owner NANJING SANHOME PHARM RES & DEV CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap